二度退出WHO、对药品征收关税，特朗普将如何动摇全球健康治理?

Group 1: Impact of Tariffs on Pharmaceutical Industry - The U.S. will impose tariffs on pharmaceuticals, which were previously excluded from broader tariffs on imports [1] - Trump believes that imposing tariffs will incentivize pharmaceutical companies to establish manufacturing facilities in the U.S. due to its large market size [1] - The Chinese pharmaceutical industry, which primarily exports intermediates and medical supplies to the U.S., will face significant challenges as the new tariffs will erode their already thin profit margins [2] Group 2: Export and Import Statistics - In 2024, China's pharmaceutical exports are projected to reach $107.964 billion, a 5.9% increase year-on-year, with the U.S. being the largest export destination at nearly $20 billion [2] - China's pharmaceutical imports are expected to decline to $91.412 billion in 2024, a 2% decrease, with a notable drop in imports from the U.S. by 4.6% [3] Group 3: Global Health and Aid Implications - The new tariffs will not only affect U.S.-China trade but also have repercussions on the global public health market, particularly impacting procurement costs for organizations like the UN and NGOs [4] - The escalation of trade tensions may hinder international cooperation on global issues such as infectious diseases and climate change, as trust between nations diminishes [4] Group 4: Uncertainty in U.S. Policy - The U.S. has withdrawn from the World Health Organization (WHO) and significantly reduced international development aid, leading to uncertainty in future U.S. health policies [5] - The reduction in U.S. aid and withdrawal from global health initiatives exposes vulnerabilities in the global public health system, necessitating reforms for resilience and sustainability [6] Group 5: Long-term Challenges in Public Health Infrastructure - The ongoing isolationist policies may lead to long-term challenges in maintaining public health infrastructure in recipient countries, complicating future recovery efforts [7]